リツキサンハイセラ/リツキサンマブセラ（リツキシマブ）の世界市場レポート 2025年：疫学、パイプライン分析、市場インサイトと予測

リツキサンハイセラ/リツキサンマブセラ（リツキシマブ）の市場規模は今後数年で急成長が見込まれます。2029年には年間平均成長率（CAGR）16%で62億7,450万米ドルに成長します。予測期間の成長は、高齢者の増加、患者の意識の高まり、新興市場の成長、政府の支援施策、標的治療に対する需要の高まりに起因すると考えられます。予測期間における主要動向としては、皮下注製剤への市場シフト、バイオシミラーとの競合激化、市場参入企業間の戦略的提携、患者中心の治療オプションへの注力、新興国地域への地理的進出などが挙げられます。

自己免疫疾患の有病率の増加は、リツキサンハイセラ/リツキサンマブセラ（リツキシマブ）市場の成長を促進すると予想されます。自己免疫疾患は、免疫系が誤って体内の細胞、組織、臓器を攻撃し、炎症や潜在的な損傷を引き起こすことで発症します。これらの疾患の増加は、免疫系に影響を与える遺伝的素因、環境要因、感染症、ライフスタイルの変化などの要因に関連しています。リツキシマブは、健康な組織を誤って攻撃する特定の免疫細胞（B細胞）を標的として枯渇させることにより、自己免疫疾患の管理に役立ちます。例えば、2023年10月にイングランド国民保健サービス（National Health Service England）が発表した報告書では、糖尿病の有病率が増加の一途をたどっていることが強調されています。イングランドでは、2021～2022年にかけて1型糖尿病患者が27万935人に増加しました。このような自己免疫疾患の罹患率の上昇は、リツキサンハイセラ/リツキサンマブセラ（リツキシマブ）市場を牽引する重要な要因です。

ヘルスケア支出の増加も、リツキサンハイセラ/リツキサンマブセラ（リツキシマブ）市場の成長を促進すると予想される要因の一つです。ヘルスケア支出には、個人的なヘルスケア、予防サービス、健康状態の改善を目的とした公衆衛生活動など、ヘルスケア商品とサービスに対するすべての支出が含まれます。この支出は、人口の高齢化、慢性疾患の増加、医療技術の進歩、薬価の高騰、医療サービスに対する需要の増加などの要因により増加しています。ヘルスケア支出の増加は、リツキサンハイセラやリツキサンマブセラのような先進治療へのアクセスを改善し、腫瘍学や自己免疫疾患の治療における効果的な治療法への需要を押し上げます。例えば、2024年5月、国家統計局の報告書によると、英国のヘルスケア支出は2022～2023年にかけて5.6％増加したのに対し、2022年の伸び率は0.9％と鈍化しました。長期的な医療社会保障支出も、2022年には実質ベースで2.8％増加しました。ヘルスケア支出の増加は、リツキサンハイセラ/リツキサンマブセラ市場の成長に寄与しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 バイオ医薬品市場における製品特性

• 分子タイプ
• 投与経路（ROA）
• 作用機序（MOA）
• 安全性と有効性

第4章 市場動向と戦略

第5章 市場：金利、インフレ、地政学的要因、新型コロナとその回復が市場に与える影響を含むマクロ経済シナリオ

第6章 世界の成長分析と戦略分析フレームワーク

• 世界のリツキサンハイセラ/リツキサンマブセラ（リツキシマブ）：PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のリツキサンハイセラ/リツキサンマブセラ（リツキシマブ）市場：成長率分析
• 世界のリツキサンハイセラ/リツキサンマブセラ（リツキシマブ）市場の実績：規模と成長、2019～2024年
• 世界のリツキサンハイセラ/リツキサンマブセラ（リツキシマブ）市場の予測：規模と成長、2024～2029年、2034年
• 世界のリツキサンハイセラ/リツキサンマブセラ（リツキシマブ）：総潜在市場規模（TAM）

第7章 世界の価格分析と予測

第8章 市場セグメンテーション

• 世界のリツキサンハイセラ/リツキサンマブセラ（リツキシマブ）市場：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 10ml
• 50ml
• 世界のリツキサンハイセラ/リツキサンマブセラ（リツキシマブ）市場：投与経路別、実績と予測、2019～2024年、2024～2029年、2034年
• 皮下
• 静脈内
• 非経口
• 世界のリツキサンハイセラ/リツキサンマブセラ（リツキシマブ）市場：流通チャネル別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院薬局
• オンライン薬局
• その他流通チャネル
• 世界のリツキサンハイセラ/リツキサンマブセラ（リツキシマブ）市場：用途別、実績と予測、2019～2024年、2024～2029年、2034年
• 非ホジキンリンパ腫
• 慢性リンパ性白血病
• 関節リウマチ
• その他

第9章 臨床適応症の世界的疫学

• 薬剤の副作用
• 臨床適応症の発症率と有病率

第10章 地域別・国別分析

• 世界のリツキサンハイセラ/リツキサンマブセラ（リツキシマブ）市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界のリツキサンハイセラ/リツキサンマブセラ（リツキシマブ）市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第11章 アジア太平洋市場

第12章 中国市場

第13章 インド市場

第14章 日本市場

第15章 オーストラリア市場

第16章 韓国市場

第17章 西欧市場

第18章 英国市場

第19章 ドイツ市場

第20章 フランス市場

第21章 東欧市場

第22章 北米市場

第23章 米国市場

第24章 カナダ市場

第25章 南米市場

第26章 中東市場

第27章 アフリカ市場

第28章 競合情勢と企業プロファイル

• リツキサンハイセラ/リツキサンマブセラ（リツキシマブ）市場：競合情勢
• リツキサンハイセラ/リツキサンマブセラ（リツキシマブ）市場：企業プロファイル
  • F. Hoffmann-La Roche AG（Genentech Inc.）

第29章 世界市場：パイプライン分析

第30章 世界の市場競合ベンチマーキングとダッシュボード

第31章 主要な合併と買収

第32章 最近の市場動向

第33章 市場の潜在力が高い国、戦略

• リツキサンハイセラ/リツキサンマブセラ（リツキシマブ）市場、2029年：新たな機会を提供する国
• リツキサンハイセラ/リツキサンマブセラ（リツキシマブ）市場、2029年：新たな機会を提供するセグメント
• リツキサンハイセラ/リツキサンマブセラ（リツキシマブ）市場、2029年：成長戦略
  • 市場動向による戦略
  • 競合の戦略

第34章 付録

Rituxan Hycela and Rituxan MabThera (rituximab) are monoclonal antibody therapies that target CD20-positive B-cells. These treatments are used for conditions such as non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and autoimmune diseases such as rheumatoid arthritis. Rituxan Hycela is a subcutaneous formulation, while Rituxan MabThera is administered intravenously.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The main formulations of Rituxan Hycela and Rituxan MabThera (rituximab) are available in 10 ml and 50 ml vials. The 10 ml vial of Rituxan Hycela is intended for patients who require a smaller dose of the medication, often suitable for those beginning treatment or needing lower dosages, allowing for personalized care. The medication is administered through subcutaneous, intravenous, and parenteral routes and is distributed through hospital pharmacies, online pharmacies, and other channels. It is used in the treatment of non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, and other conditions.

The rituxan hycela, rituxan mabthera (rituximab) market research report is one of a series of new reports from The Business Research Company that provides rituxan hycela, rituxan mabthera (rituximab) market statistics, including the rituxan hycela, rituxan mabthera (rituximab) industry's global market size, regional shares, competitors with a rituxan hycela, rituxan mabthera (rituximab) market share, detailed rituxan hycela, rituxan mabthera (rituximab) market segments, market trends and opportunities, and any further data you may need to thrive in the rituxan hycela, rituxan mabthera (rituximab) industry. This rituxan hycela, rituxan mabthera (rituximab) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The rituxan hycela, rituxan mabthera (rituximab) market size is expected to see rapid growth in the next few years. It will grow to $6,274.5 million in 2029 at a compound annual growth rate (CAGR) of 16%. The growth in the forecast period can be attributed to the rising geriatric population, increasing patient awareness, emerging market growth, supportive government policies, and growing demand for targeted therapies. Major trends in the forecast period include market shifts towards subcutaneous formulations, increased competition from biosimilars, strategic collaborations among market players, focus on patient-centric treatment options, and geographic expansion into developing regions.

The increasing prevalence of autoimmune diseases is expected to drive the growth of the Rituxan Hycela and Rituxan MabThera (rituximab) market. Autoimmune diseases occur when the immune system mistakenly attacks the body's own cells, tissues, or organs, leading to inflammation and potential damage. The rise in these conditions is linked to factors such as genetic predisposition, environmental factors, infections, and lifestyle changes that impact the immune system. Rituximab helps manage autoimmune diseases by targeting and depleting specific immune cells (B-cells) that mistakenly attack healthy tissues. For example, in October 2023, a report from the National Health Service England highlighted the ongoing rise in the prevalence of diabetes. In England, the number of people with type 1 diabetes increased to 270,935 between 2021 and 2022. This rising incidence of autoimmune diseases is a key factor driving the market for Rituxan Hycela and Rituxan MabThera (rituximab).

The growing healthcare expenditure is another factor expected to propel the growth of the Rituxan Hycela and Rituxan MabThera (rituximab) market. Healthcare expenditure encompasses all spending on healthcare goods and services, including personal health care, preventive services, and public health activities, which aim to improve health outcomes. This expenditure is increasing due to factors such as an aging population, the rise of chronic diseases, advancements in medical technology, high drug prices, and increased demand for healthcare services. Higher healthcare spending improves access to advanced treatments such as Rituxan Hycela and Rituxan MabThera, boosting demand for effective therapies in the treatment of oncology and autoimmune diseases. For instance, in May 2024, a report from the Office for National Statistics noted that healthcare expenditure in the UK rose by 5.6% from 2022 to 2023, compared to a slower growth rate of 0.9% in 2022. Long-term health and social care expenditure also saw an increase of 2.8% in real terms in 2022. The rise in healthcare spending is contributing to the growth of the Rituxan Hycela and Rituxan MabThera market.

A significant trend in the Rituxan Hycela and Rituxan MabThera (rituximab) market is the development of biosimilar anti-CD20 monoclonal antibodies, which offer cost-effective alternatives and improve patient access to treatment. Biosimilars are biologic drugs highly similar to reference products such as Rituxan, designed to target CD20 on B-cells and provide a more affordable treatment option. For example, in June 2022, Amgen received approval from the US Food and Drug Administration (FDA) for RIABNI (rituximab-arrx), a biosimilar to Rituxan, for use in combination with methotrexate in adults with moderate to severely active rheumatoid arthritis who have not responded well to one or more tumor necrosis factor (TNF) antagonist therapies. RIABNI is a biosimilar version of Rituxan, containing the same amino acid sequence and available in the same dosage form, strength, and administration route. The development of such biosimilars is expected to further drive the market for Rituxan Hycela and Rituxan MabThera.

The key company operating in the rituxan hycela, rituxan mabthera (rituximab) market is F. Hoffmann-La Roche AG (Genentech Inc.)

North America was the largest region in the rituxan hycela, rituxan mabthera (rituximab) market in 2024. The regions covered in rituxan hycela and rituxan mabthera (rituximab) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the rituxan hycela and rituxan mabthera (rituximab) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The rituxan hycela and rituxan mabthera (rituximab) market consists of sales of MabThera 1600 mg and ritunxan hycela (rituximab and hyaluronidase human injection). Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Rituxan Hycela, Rituxan Mabthera (Rituximab) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on rituxan hycela, rituxan mabthera (rituximab) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for rituxan hycela, rituxan mabthera (rituximab) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The rituxan hycela, rituxan mabthera (rituximab) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: 10ml; 50ml
• 2) By Route Of Administration: Subcutaneous; Intravenous; Parenteral
• 3) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Others Distribution Channel
• 4) By Application: Non-Hodgkin Lymphoma; Chronic Lymphocytic Leukemia; Rheumatoid Arthritis; Other Applications
• Companies Mentioned: F. Hoffmann-La Roche AG (Genentech Inc.)
• Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Rituxan Hycela, Rituxan Mabthera (Rituximab) Market Characteristics

3. Rituxan Hycela, Rituxan Mabthera (Rituximab) Market Biologic Drug Characteristics

• 3.1. Molecule Type
• 3.2. Route Of Administration (ROA)
• 3.3. Mechanism Of Action (MOA)
• 3.4. Safety And Efficacy

4. Rituxan Hycela, Rituxan Mabthera (Rituximab) Market Trends And Strategies

5. Rituxan Hycela, Rituxan Mabthera (Rituximab) Market -Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

6. Global Rituxan Hycela, Rituxan Mabthera (Rituximab) Growth Analysis And Strategic Analysis Framework

• 6.1. Global Rituxan Hycela, Rituxan Mabthera (Rituximab) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 6.2. Analysis Of End Use Industries
• 6.3. Global Rituxan Hycela, Rituxan Mabthera (Rituximab) Market Growth Rate Analysis
• 6.4. Global Rituxan Hycela, Rituxan Mabthera (Rituximab) Historic Market Size and Growth, 2019 - 2024, Value ($ Million)
• 6.5. Global Rituxan Hycela, Rituxan Mabthera (Rituximab) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Million)
• 6.6. Global Rituxan Hycela, Rituxan Mabthera (Rituximab) Total Addressable Market (TAM)

7. Global Rituxan Hycela, Rituxan Mabthera (Rituximab) Pricing Analysis & Forecasts

8. Rituxan Hycela, Rituxan Mabthera (Rituximab) Market Segmentation

• 8.1. Global Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 10ml
• 50ml
• 8.2. Global Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• Subcutaneous
• Intravenous
• Parenteral
• 8.3. Global Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• Hospital Pharmacy
• Online Pharmacy
• Others Distribution Channel
• 8.4. Global Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• Non-Hodgkin Lymphoma
• Chronic Lymphocytic Leukemia
• Rheumatoid Arthritis
• Other Applications

9. Global Rituxan Hycela, Rituxan Mabthera (Rituximab) Epidemiology Of Clinical Indications

• 9.1. Drug Side Effects
• 9.2. Incidence And Prevalence of Clinical Indications

10. Rituxan Hycela, Rituxan Mabthera (Rituximab) Market Regional And Country Analysis

• 10.1. Global Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 10.2. Global Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

11. Asia-Pacific Rituxan Hycela, Rituxan Mabthera (Rituximab) Market

• 11.1. Asia-Pacific Rituxan Hycela, Rituxan Mabthera (Rituximab) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 11.3. Asia-Pacific Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 11.4. Asia-Pacific Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

12. China Rituxan Hycela, Rituxan Mabthera (Rituximab) Market

• 12.1. China Rituxan Hycela, Rituxan Mabthera (Rituximab) Market Overview
• 12.2. China Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Million
• 12.3. China Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Million
• 12.4. China Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Million

13. India Rituxan Hycela, Rituxan Mabthera (Rituximab) Market

• 13.1. India Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 13.2. India Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 13.3. India Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

14. Japan Rituxan Hycela, Rituxan Mabthera (Rituximab) Market

• 14.1. Japan Rituxan Hycela, Rituxan Mabthera (Rituximab) Market Overview
• 14.2. Japan Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 14.3. Japan Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 14.4. Japan Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

15. Australia Rituxan Hycela, Rituxan Mabthera (Rituximab) Market

• 15.1. Australia Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 15.2. Australia Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 15.3. Australia Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

16. South Korea Rituxan Hycela, Rituxan Mabthera (Rituximab) Market

• 16.1. South Korea Rituxan Hycela, Rituxan Mabthera (Rituximab) Market Overview
• 16.2. South Korea Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 16.3. South Korea Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 16.4. South Korea Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

17. Western Europe Rituxan Hycela, Rituxan Mabthera (Rituximab) Market

• 17.1. Western Europe Rituxan Hycela, Rituxan Mabthera (Rituximab) Market Overview
• 17.2. Western Europe Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 17.3. Western Europe Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 17.4. Western Europe Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

18. UK Rituxan Hycela, Rituxan Mabthera (Rituximab) Market

• 18.1. UK Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 18.2. UK Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 18.3. UK Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

19. Germany Rituxan Hycela, Rituxan Mabthera (Rituximab) Market

• 19.1. Germany Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 19.2. Germany Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 19.3. Germany Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

20. France Rituxan Hycela, Rituxan Mabthera (Rituximab) Market

• 20.1. France Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 20.2. France Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 20.3. France Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

21. Eastern Europe Rituxan Hycela, Rituxan Mabthera (Rituximab) Market

• 21.1. Eastern Europe Rituxan Hycela, Rituxan Mabthera (Rituximab) Market Overview
• 21.2. Eastern Europe Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 21.3. Eastern Europe Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 21.4. Eastern Europe Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

22. North America Rituxan Hycela, Rituxan Mabthera (Rituximab) Market

• 22.1. North America Rituxan Hycela, Rituxan Mabthera (Rituximab) Market Overview
• 22.2. North America Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 22.3. North America Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 22.4. North America Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

23. USA Rituxan Hycela, Rituxan Mabthera (Rituximab) Market

• 23.1. USA Rituxan Hycela, Rituxan Mabthera (Rituximab) Market Overview
• 23.2. USA Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 23.3. USA Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 23.4. USA Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

24. Canada Rituxan Hycela, Rituxan Mabthera (Rituximab) Market

• 24.1. Canada Rituxan Hycela, Rituxan Mabthera (Rituximab) Market Overview
• 24.2. Canada Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 24.3. Canada Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 24.4. Canada Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

25. South America Rituxan Hycela, Rituxan Mabthera (Rituximab) Market

• 25.1. South America Rituxan Hycela, Rituxan Mabthera (Rituximab) Market Overview
• 25.2. South America Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 25.3. South America Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 25.4. South America Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

26. Middle East Rituxan Hycela, Rituxan Mabthera (Rituximab) Market

• 26.1. Middle East Rituxan Hycela, Rituxan Mabthera (Rituximab) Market Overview
• 26.2. Middle East Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 26.3. Middle East Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 26.4. Middle East Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

27. Africa Rituxan Hycela, Rituxan Mabthera (Rituximab) Market

• 27.1. Africa Rituxan Hycela, Rituxan Mabthera (Rituximab) Market Overview
• 27.2. Africa Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 27.3. Africa Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 27.4. Africa Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

28. Rituxan Hycela, Rituxan Mabthera (Rituximab) Market Competitive Landscape And Company Profiles

• 28.1. Rituxan Hycela, Rituxan Mabthera (Rituximab) Market Competitive Landscape
• 28.2. Rituxan Hycela, Rituxan Mabthera (Rituximab) Market Company Profiles
  • 28.2.1. F. Hoffmann-La Roche AG (Genentech Inc.) Overview, Products and Services, Strategy and Financial Analysis

29. Global Rituxan Hycela, Rituxan Mabthera (Rituximab) Market Pipeline Analysis

• 29.1. High Level Clinic Trail Information

30. Global Rituxan Hycela, Rituxan Mabthera (Rituximab) Market Competitive Benchmarking And Dashboard

31. Key Mergers And Acquisitions In The Rituxan Hycela, Rituxan Mabthera (Rituximab) Market

32. Recent Developments In The Rituxan Hycela, Rituxan Mabthera (Rituximab) Market

33. Rituxan Hycela, Rituxan Mabthera (Rituximab) Market High Potential Countries, Segments and Strategies

• 33.1 Rituxan Hycela, Rituxan Mabthera (Rituximab) Market In 2029 - Countries Offering Most New Opportunities
• 33.2 Rituxan Hycela, Rituxan Mabthera (Rituximab) Market In 2029 - Segments Offering Most New Opportunities
• 33.3 Rituxan Hycela, Rituxan Mabthera (Rituximab) Market In 2029 - Growth Strategies
  • 33.3.1 Market Trend Based Strategies
  • 33.3.2 Competitor Strategies

34. Appendix

• 34.1. Abbreviations
• 34.2. Currencies
• 34.3. Historic And Forecast Inflation Rates
• 34.4. Research Inquiries
• 34.5. The Business Research Company
• 34.6. Copyright And Disclaimer